RxDoctor Payments Data

Hassan Borghei, DO

Gastroenterology · Cocoa Beach, FLNPI 1093913550

Payments from drug & device makers

$7,214in general payments, 2019–2025

Across 433 payments — averaging $16.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$695
  • Bristol Myers Squibb$647
  • Takeda Pharmaceuticals U.S.A., Inc.$518
  • Johnson & Johnson$503
  • Nestle Healthcare Nutrition Inc.$323
  • plus $2K from 23 others

What the payments were for

  • Consulting fees$240%
  • Food & beverage$7,16099%
  • Education$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,214 in reported general payments places this provider in the 65th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$134,435
Medicare patients
573
Services billed
1,912

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide31$22,956
ZenpepLipase/Protease/Amylase12$19,130
Mesalamine21$5,807
Dexlansoprazole DrDexlansoprazole12$4,815
Pantoprazole Sodium287$4,740
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates65$3,772
Balsalazide Disodium16$2,567
Famotidine124$1,716
Ursodiol12$1,596
Omeprazole123$1,391
Esomeprazole Magnesium31$1,049
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl50$753
Mesalamine ErMesalamine12$548
Dicyclomine Hcl13$185
Metoclopramide Hcl16$55

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$2,673$22,95631 claims
Aimmune Therapeutics, Inc.Zenpep$16$19,13012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Cocoa Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →